留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

异基因造血干细胞移植术后发生甲状腺功能亢进1例报告并文献复习

郭芳 郑永江

郭芳, 郑永江. 异基因造血干细胞移植术后发生甲状腺功能亢进1例报告并文献复习[J]. 器官移植, 2015, 6(3): 194-196,205. doi: 10.3969/j.issn.1674-7445.2015.03.013
引用本文: 郭芳, 郑永江. 异基因造血干细胞移植术后发生甲状腺功能亢进1例报告并文献复习[J]. 器官移植, 2015, 6(3): 194-196,205. doi: 10.3969/j.issn.1674-7445.2015.03.013
Guo Fang, Zheng Yongjiang. Hyperthyroidism after allogeneic hematopoietic stem cell transplantation: a case report and literature review[J]. ORGAN TRANSPLANTATION, 2015, 6(3): 194-196,205. doi: 10.3969/j.issn.1674-7445.2015.03.013
Citation: Guo Fang, Zheng Yongjiang. Hyperthyroidism after allogeneic hematopoietic stem cell transplantation: a case report and literature review[J]. ORGAN TRANSPLANTATION, 2015, 6(3): 194-196,205. doi: 10.3969/j.issn.1674-7445.2015.03.013

异基因造血干细胞移植术后发生甲状腺功能亢进1例报告并文献复习

doi: 10.3969/j.issn.1674-7445.2015.03.013
详细信息
    通讯作者:

    郑永江,Email:zhengyongjiang@aliyun.com

  • 中图分类号: R617

Hyperthyroidism after allogeneic hematopoietic stem cell transplantation: a case report and literature review

More Information
  • 摘要:   目的  探讨异基因造血干细胞移植术后发生甲状腺功能亢进(甲亢)的诊治特点。   方法  回顾性分析2008年12月在中山大学附属第三医院血液科行异基因造血干细胞移植术后发生甲亢的1例女性患者的临床资料,总结分析该例患者的临床表现、实验室检查以及诊治经过,并复习相关文献。   结果  该患者异基因造血干细胞移植术后39个月出现甲亢症状,患者有甲亢特异性临床表现和实验室检查结果,诊断为弥漫性毒性甲状腺肿(Graves病),给予药物治疗后效果良好。   结论  异基因造血干细胞移植术后发生甲亢临床少见,有特异性临床表现,确诊主要依靠实验室检查。该病如早期诊断和治疗,疗效良好。

     

  • [1] Effraimidis G, Wiersinga WM. Mechanisms in endocrinology:autoimmune thyroid disease:old and new players[J]. Eur J Endocrinol,2014,170(6):R241-R252. doi: 10.1530/EJE-14-0047
    [2] Au WY, Lie AK, Kung AW, et al. Autoimmune thyroid dysfunction after hematopoietic stem cell transplantation[J]. Bone Marrow Transplant,2005,35(4):383-388. doi: 10.1038/sj.bmt.1704766
    [3] Tauchmanovà L, Selleri C, De Rosa G, et al. Endocrine disorders during the first year after autologous stem-cell transplant[J]. Am J Med,2005,118(6):664-670. doi: 10.1016/j.amjmed.2005.02.009
    [4] Hou HA, Tang JL, Hsu SC, et al. Acquisition and cure of autoimmune disease following allogeneic hematopoietic stem cell transplantation[J]. J Formos Med Assoc,2007,106(9):779-783. doi: 10.1016/S0929-6646(08)60040-6
    [5] Orio F, Muscogiuri G, Palomba S, et al. Endocrinopathies after allogeneic and autologous transplantation of hematopoietic stem cells[J]. Scientific World J, 2014:282147. http://cn.bing.com/academic/profile?id=2083880773&encoded=0&v=paper_preview&mkt=zh-cn
    [6] Gunasekaran U, Agarwal N, Jagasia MH, et al. Endocrine complications in long-term survivors after allogeneic stem cell transplant[J]. Semin Hematol,2012,49(1):66-72. doi: 10.1053/j.seminhematol.2011.10.010
    [7] Hon C, Yau K, Chan EY, et al. Graves' ophthalmopathy after allogeneic stem cell transplantation[J]. Ann Hematol,2006,85(12):887-888. doi: 10.1007/s00277-006-0183-4
    [8] Vardizer Y, Lupetti A, Vandelanotte S, et al. Graves' orbitopathy in a patient with adrenoleukodystrophy after bone marrow transplantation[J]. Eur J Endocrinol,2009,161(2):369-373. doi: 10.1530/EJE-08-0944
    [9] Feng YH, Su BA, Lin CY, et al. Hyperthyroidism as a latent complication of autologous hematopoietic stem cell transplantation[J]. Int J Hematol,2008,88(2):237-239. doi: 10.1007/s12185-008-0096-1
    [10] Perz JB, Marin D, Szydlo RM, et al. Incidence of hyperthyroidism after unrelated donor allogeneic stem cell transplantation[J]. Leuk Res,2007,31(10):1433-1436. doi: 10.1016/j.leukres.2007.03.004
    [11] Jung YJ, Jeon YJ, Cho WK, et al. Risk factors for short term thyroid dysfunction after hematopoietic stem cell transplantation in children[J]. Korean J Pediatr,2013,56(7):298-303. doi: 10.3345/kjp.2013.56.7.298
    [12] Tailor IK, Akil M, Rennie I, et al. Reconstitution Graves' disease following autologous haematopoietic stem cell transplantation for severe diffuse systemic sclerosis[J]. QJM,2012,105(4):369-371. doi: 10.1093/qjmed/hcr050
    [13] De Waele S, Van den Bruel A, Selleslag D, et al. Acute thyrotoxicosis after SCT[J]. Bone Marrow Transplant,2009,43(8):663-664. doi: 10.1038/bmt.2008.374
    [14] Devereaux D, Tewelde SZ. Hyperthyroidism and thyrotoxicosis[J]. Emerg Med Clin North Am,2014,32(2):277-292. doi: 10.1016/j.emc.2013.12.001
    [15] Lee HS, Hwang JS. The treatment of Graves' disease in children and adolescents[J]. Ann Pediatr Endocrinol Metab,2014,19(3):122-126. doi: 10.6065/apem.2014.19.3.122
    [16] Muldoon BT, Mai VQ, Burch HB. Management of Graves' disease:an overview and comparison of clinical practice guidelines with actual practice trends[J]. Endocrinol Metab Clin North Am,2014,43(2):495-516. doi: 10.1016/j.ecl.2014.02.001
    [17] Vaidya B, Pearce SH. Diagnosis and management of thyrotoxicosis[J]. BMJ,2014,349:g5128. doi: 10.1136/bmj.g5128
    [18] Berisso GA, van Lint MT, Bacigalupo A, et al. Adoptive autoimmune hyperthyroidism following allogeneic stem cell transplantation from an HLA-identical sibling with Graves' disease[J]. Bone Marrow Transplant,1999,23(10):1091-1092. doi: 10.1038/sj.bmt.1701760
    [19] Ishikawa F, Shigematsu H, Gondo H, et al. Autoreactive antibodies following autologous peripheral blood stem cell transplantation[J]. Bone Marrow Transplant,1998,22(7):729-731. doi: 10.1038/sj.bmt.1701409
    [20] Au WY, Lie AK, Kung AW, et al. Thyrotoxic periodic paralysis after allogeneic haematopoietic stem cell transplantation[J]. Br J Haematol,2005,129(1):160-161. doi: 10.1111/bjh.2005.129.issue-1
  • 加载中
计量
  • 文章访问数:  123
  • HTML全文浏览量:  133
  • PDF下载量:  3
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-02-01
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2015-05-15

目录

    /

    返回文章
    返回